CP-132,484

CP-132,484

CP-132,484 is a drug that was developed by Pfizer in the late 1990s. It is a member of the quinolone class of antibiotics, which are used to treat a variety of bacterial infections.

History

CP-132,484 was first synthesized by Pfizer in 1996 as part of their ongoing research into quinolone antibiotics. The drug was developed in response to the growing need for new antibiotics to combat drug-resistant bacteria.

Pharmacology

Like other quinolones, CP-132,484 works by inhibiting the DNA gyrase and topoisomerase IV enzymes, which are essential for bacterial DNA replication. This prevents the bacteria from reproducing and allows the body's immune system to eliminate the infection.

Clinical Trials

CP-132,484 underwent Phase I clinical trials in the late 1990s. These trials are designed to test the safety of a new drug in healthy volunteers. The results of these trials have not been publicly released.

Current Status

As of 2021, CP-132,484 is not currently on the market. The reasons for this are not publicly known, but it is possible that the drug did not meet the necessary safety and efficacy standards in later-stage clinical trials.

See Also

• Quinolone
• Pfizer
• DNA gyrase
• Topoisomerase IV
• Phase I clinical trial

‎